These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 34864445)

  • 1. A case of VEXAS syndrome associated with EBV-associated hemophagocytic lymphohistiocytosis.
    Kao RL; Jacobsen AA; Billington CJ; Yohe SL; Beckman AK; Vercellotti GM; Pearson DR
    Blood Cells Mol Dis; 2022 Mar; 93():102636. PubMed ID: 34864445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term remission of VEXAS syndrome achieved by a single course of CHOP therapy: A case report.
    Miyoshi Y; Kise T; Morita K; Okada H; Imadome KI; Tsuchida N; Maeda A; Uchiyama Y; Kirino Y; Matsumoto N; Yokogawa N
    Mod Rheumatol Case Rep; 2023 Dec; 8(1):199-204. PubMed ID: 37548220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus-related hemophagocytic lymphohistiocytosis complicated with coronary artery dilation and acute renal injury in a boy with a novel X-linked inhibitor of apoptosis protein (XIAP) variant: a case report.
    Chen RY; Li XZ; Lin Q; Zhu Y; Shen YY; Xu QY; Zhu XM; Bai ZJ; Li Y
    BMC Pediatr; 2020 Oct; 20(1):456. PubMed ID: 33008347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rescue of HLH with T and B Lymphocyte Involvement Due to Epstein-Barr Virus by PD-1 Inhibitor/Ruxolitinib and Rituximab Combination Regimens: A Case Report.
    Zhu M; Zhang J; Shi Q; Sun X; Wang H; Sun M; Liu Y
    Iran J Immunol; 2023 Dec; 20(4):466-472. PubMed ID: 37873944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens.
    Chellapandian D; Das R; Zelley K; Wiener SJ; Zhao H; Teachey DT; Nichols KE;
    Br J Haematol; 2013 Aug; 162(3):376-82. PubMed ID: 23692048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis subsequent to rabbit antithymocyte globulin administration and successfully treated with rituximab in a patient with aplastic anemia].
    Nagata H; Fujino T; Muramatsu A; Kawaji Y; Kuriyama K; Oshiro M; Hirakawa Y; Iwai T; Uchiyama H
    Rinsho Ketsueki; 2018; 59(4):407-413. PubMed ID: 29743400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful use of rituximab for refractory hemophagocytic lymphohistiocytosis in a melanoma patient treated with targeted therapy.
    Tejedor I; Tedbirt B; Carvalho P; Duval-Modeste AB; Joly P; Hébert V
    Melanoma Res; 2022 Dec; 32(6):485-487. PubMed ID: 36125885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ileal mass-like lesion induced by Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in a patient with aplastic anemia.
    Min KW; Jung HY; Han HS; Hwang TS; Kim SY; Kim WS; Lim SD; Kim WY
    APMIS; 2015 Jan; 123(1):81-6. PubMed ID: 25243347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis with severe cardiac complications.
    Kawamura Y; Miura H; Matsumoto Y; Uchida H; Kudo K; Hata T; Ito Y; Kimura H; Yoshikawa T
    BMC Pediatr; 2016 Oct; 16(1):172. PubMed ID: 27793118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case Report: Coexistence of Multiple Myeloma and Auricular Chondritis in VEXAS Syndrome.
    Matsumoto H; Fujita Y; Fukatsu M; Ikezoe T; Yokose K; Asano T; Tsuchida N; Maeda A; Yoshida S; Hashimoto H; Temmoku J; Matsuoka N; Yashiro-Furuya M; Sato S; Murakami M; Sato H; Sakuma C; Kawashima K; Shakespear N; Uchiyama Y; Watanabe H; Kirino Y; Matsumoto N; Migita K
    Front Immunol; 2022; 13():897722. PubMed ID: 35757758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emergence of CD20-/CD19- tumor cells after rituximab therapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosis.
    Yamamoto N; Nishimura N; Takeuchi M; Ito T; Yokozaki H; Hirase S; Kubokawa I; Mori T; Yanai T; Hayakawa A; Takeshima Y; Nishio H; Matsuo M; Imadome K; Iijima K
    Eur J Pediatr; 2014 Dec; 173(12):1615-8. PubMed ID: 24169729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis.
    Balamuth NJ; Nichols KE; Paessler M; Teachey DT
    J Pediatr Hematol Oncol; 2007 Aug; 29(8):569-73. PubMed ID: 17762500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous Recovery of Hemophagocytic Lymphohistiocytosis Due to Primary Epstein-Barr Virus Infection in an Adult Patient.
    Matsuo Y; Iwanami K; Hiraoka E; Oda R
    Am J Case Rep; 2021 Oct; 22():e933272. PubMed ID: 34657119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemophagocytic Lymphohistiocytosis: an Under-recognized and Life-threatening Condition.
    Poudyal BS; Poudel B; Tuladhar S; Rijal SS; Shrestha GS; Joshi U
    J Nepal Health Res Counc; 2023 Mar; 20(3):794-796. PubMed ID: 36974876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult Epstein-Barr virus-associated HLH patients.
    Yao S; He L; Zhang R; Liu M; Hua Z; Zou H; Wang Z; Wang Y
    Ann Med; 2023 Dec; 55(1):89-100. PubMed ID: 36533966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analysis of sintilimab combined with ruxolitinib as compassionate therapy for 12 adults with EBV-associated hemophagocytic lymphohistiocytosis.
    Xu Y; Li W; Gan J; He X; Huang X
    Ann Hematol; 2023 Dec; 102(12):3325-3333. PubMed ID: 37787838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS syndrome) with prominent supraglottic larynx involvement: a case-based review.
    Guerrero-Bermúdez CA; Cardona-Cardona AF; Ariza-Parra EJ; Arostegui JI; Mensa-Vilaro A; Yague J; Vásquez G; Muñoz-Vahos CH
    Clin Rheumatol; 2022 Nov; 41(11):3565-3572. PubMed ID: 35986821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual Threat of Epstein-Barr Virus: an Autopsy Case Report of HIV-Positive Plasmablastic Lymphoma Complicating EBV-Associated Hemophagocytic Lymphohistiocytosis.
    Koizumi Y; Imadome KI; Ota Y; Minamiguchi H; Kodama Y; Watanabe D; Mikamo H; Uehira T; Okada S; Shirasaka T
    J Clin Immunol; 2018 May; 38(4):478-483. PubMed ID: 29687211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab-containing immuno-chemotherapy regimens are effective for the elimination of EBV for EBV-HLH with only and mainly B lymphocytes of EBV infection.
    Meng GQ; Wang JS; Wang YN; Wei N; Wang Z
    Int Immunopharmacol; 2021 Jul; 96():107606. PubMed ID: 33826999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome.
    Patel N; Dulau-Florea A; Calvo KR
    Semin Hematol; 2021 Oct; 58(4):204-211. PubMed ID: 34802541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.